Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD

INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...

Full description

Saved in:
Bibliographic Details
Published in:Kidney Int Rep
Main Authors: Hanset, Nicolas, Esteve, Emmanuel, Plaisier, Emmanuelle, Johanet, Catherine, Michel, Pierre-Antoine, Boffa, Jean-Jacques, Fievet, Patrick, Mesnard, Laurent, Morelle, Johann, Ronco, Pierre, Dahan, Karine
Format: Artigo
Language:Inglês
Published: Elsevier 2019
Subjects:
Clinical Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056852/
https://ncbi.nlm.nih.gov/pubmed/32154454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2019.12.006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items